Veracyte Q2 revenue $55.1M (+166% YoY); raises 2021 guidance to $200-208M

VERACYTE, INC.

2021-Q2 EPS reported -$0.78 revenue$91,808,000

Total revenue $55.1M, up 166% YoY; net loss $9.0M ($0.13 per share) improved 18%.
Genomic test volume 20,856, up 215% YoY and 44% sequentially.
Raises FY2021 revenue guidance to $200-208M from $190-200M.
Received Medicare coverage for Decipher Bladder; signed managed care contract for Decipher Prostate (~20M members).
Planned HalioDx acquisition announced; new CFO, CBO, CIO appointed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.